UY36286A - Tratamientos médicos basados en anamorelina - Google Patents

Tratamientos médicos basados en anamorelina

Info

Publication number
UY36286A
UY36286A UY0001036286A UY36286A UY36286A UY 36286 A UY36286 A UY 36286A UY 0001036286 A UY0001036286 A UY 0001036286A UY 36286 A UY36286 A UY 36286A UY 36286 A UY36286 A UY 36286A
Authority
UY
Uruguay
Prior art keywords
anamoreline
medical treatments
based medical
treatments
anamorelin
Prior art date
Application number
UY0001036286A
Other languages
English (en)
Spanish (es)
Inventor
Mann William
Friend John
Lu Ming
Duus Elizabeth
Polvino William
Allen Suzan
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of UY36286A publication Critical patent/UY36286A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UY0001036286A 2014-09-04 2015-09-02 Tratamientos médicos basados en anamorelina UY36286A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
UY36286A true UY36286A (es) 2016-02-29

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036286A UY36286A (es) 2014-09-04 2015-09-02 Tratamientos médicos basados en anamorelina

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3188599B1 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR101881264B1 (enExample)
CN (5) CN107375285A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (1) GEP20186939B (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
BR112022005457A2 (pt) * 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したc−反応性蛋白質の低減方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗(美国)有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN104470524A (zh) 2012-05-25 2015-03-25 拉夸里亚创药株式会社 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések

Also Published As

Publication number Publication date
CY1122746T1 (el) 2021-03-12
CL2017000494A1 (es) 2017-09-15
CN109172575A (zh) 2019-01-11
ECSP17019893A (es) 2017-05-31
US10278964B2 (en) 2019-05-07
US20190175574A1 (en) 2019-06-13
JP2017526695A (ja) 2017-09-14
CR20170121A (es) 2017-07-17
ME03597B (me) 2020-07-20
IL250692B (en) 2019-05-30
EP3188599A4 (en) 2017-10-11
CN107205389A (zh) 2017-09-26
MX361741B (es) 2018-12-14
EP3590338A3 (en) 2020-03-18
BR112017003552A2 (pt) 2017-12-05
SI3188599T1 (sl) 2020-02-28
PT3188599T (pt) 2020-01-15
UA120765C2 (uk) 2020-02-10
JP2021080281A (ja) 2021-05-27
MD20170025A2 (ro) 2017-07-31
IL250692A0 (en) 2017-04-30
PL3188599T3 (pl) 2020-06-01
TWI639429B (zh) 2018-11-01
US10894041B2 (en) 2021-01-19
CA2959158A1 (en) 2016-03-10
NI201700024A (es) 2017-07-18
PH12017500392B1 (en) 2018-08-31
EP3188599A1 (en) 2017-07-12
SG11201701567UA (en) 2017-03-30
US20210093627A1 (en) 2021-04-01
US20170296526A1 (en) 2017-10-19
NZ729673A (en) 2023-09-29
AU2015312231A1 (en) 2017-03-23
WO2016036598A1 (en) 2016-03-10
PE20171109A1 (es) 2017-08-07
MA40607B1 (fr) 2019-11-29
MY187167A (en) 2021-09-07
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
CN107375285A (zh) 2017-11-24
PH12017500392A1 (en) 2017-07-17
ES2761777T3 (es) 2020-05-21
TN2017000040A1 (en) 2018-07-04
KR101881264B1 (ko) 2018-07-23
LT3188599T (lt) 2019-12-10
JO3541B1 (ar) 2020-07-05
US20240024303A1 (en) 2024-01-25
JP6923486B2 (ja) 2021-08-18
EP3188599B1 (en) 2019-10-02
MD4710B1 (ro) 2020-09-30
MX2017002825A (es) 2017-09-28
JP2018154655A (ja) 2018-10-04
SV2017005400A (es) 2017-04-20
US11723902B2 (en) 2023-08-15
TW201613587A (en) 2016-04-16
KR20180085047A (ko) 2018-07-25
US20160067236A1 (en) 2016-03-10
CN113577073A (zh) 2021-11-02
KR20170047372A (ko) 2017-05-04
KR20210035923A (ko) 2021-04-01
JP7044918B2 (ja) 2022-03-30
EP3590338A2 (en) 2020-01-08
CO2017003263A2 (es) 2017-07-28
AP2017009772A0 (en) 2017-02-28
KR102234319B1 (ko) 2021-04-01
MD4710C1 (ro) 2021-04-30
KR102307275B1 (ko) 2021-09-30
AU2015312231B2 (en) 2017-10-19
EA035578B1 (ru) 2020-07-09
US9675600B2 (en) 2017-06-13
JP6356907B2 (ja) 2018-07-11
RS59751B1 (sr) 2020-02-28
GEP20186939B (en) 2018-12-25
HRP20192345T1 (hr) 2020-03-20
DOP2017000055A (es) 2017-08-15
AR103118A1 (es) 2017-04-19
HUE046894T2 (hu) 2020-04-28
CN113577074A (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL249065A0 (en) Combination therapies for the treatment of cancer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL255261A0 (en) Methods for treating cancer
ECSP17073743A (es) Moduladores de k-ras
PL3288581T3 (pl) Sposób leczenia nowotworu
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
IL258521B1 (en) Combination therapy for the treatment of cancer
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
UY36286A (es) Tratamientos médicos basados en anamorelina
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
ECSP17015977A (es) Terapia de combinacion
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
IL265938A (en) Lasofoxifene treatment of er+ breast cancer
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
BR112016018754A2 (pt) método de tratamento de um câncer com vascularização
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230427